Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.
2.

Mutation and structure guided discovery of an antiviral small molecule that mimics an essential C-Terminal tripeptide of the vaccinia D4 processivity factor.

Nuth M, Guan H, Xiao Y, Kulp JL 3rd, Parker MH, Strobel ED, Isaacs SN, Scott RW, Reitz AB, Ricciardi RP.

Antiviral Res. 2019 Feb;162:178-185. doi: 10.1016/j.antiviral.2018.12.011. Epub 2018 Dec 20.

PMID:
30578797
3.

Identifying Host Factors Associated with DNA Replicated During Virus Infection.

Reyes ED, Kulej K, Pancholi NJ, Akhtar LN, Avgousti DC, Kim ET, Bricker DK, Spruce LA, Koniski SA, Seeholzer SH, Isaacs SN, Garcia BA, Weitzman MD.

Mol Cell Proteomics. 2017 Dec;16(12):2079-2097. doi: 10.1074/mcp.M117.067116. Epub 2017 Oct 2.

4.

A novel target and approach for identifying antivirals against molluscum contagiosum virus.

Guan H, Nuth M, Zhukovskaya N, Saw YL, Bell E, Isaacs SN, Ricciardi RP.

Antimicrob Agents Chemother. 2014 Dec;58(12):7383-9. doi: 10.1128/AAC.03660-14. Epub 2014 Sep 29.

5.

Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

Xiao Y, Zeng Y, Alexander E, Mehta S, Joshi SB, Buchman GW, Volkin DB, Middaugh CR, Isaacs SN.

Vaccine. 2013 Jan 2;31(2):319-26. doi: 10.1016/j.vaccine.2012.11.007. Epub 2012 Nov 12.

6.

Enzyme-linked immunosorbent assay (ELISA) and blocking with bovine serum albumin (BSA)--not all BSAs are alike.

Xiao Y, Isaacs SN.

J Immunol Methods. 2012 Oct 31;384(1-2):148-51. doi: 10.1016/j.jim.2012.06.009. Epub 2012 Jun 23.

7.

Working safely with vaccinia virus: laboratory technique and review of published cases of accidental laboratory infections.

Isaacs SN.

Methods Mol Biol. 2012;890:1-22. doi: 10.1007/978-1-61779-876-4_1. Review.

PMID:
22688758
8.

Elucidating the role of the complement control protein in monkeypox pathogenicity.

Hudson PN, Self J, Weiss S, Braden Z, Xiao Y, Girgis NM, Emerson G, Hughes C, Sammons SA, Isaacs SN, Damon IK, Olson VA.

PLoS One. 2012;7(4):e35086. doi: 10.1371/journal.pone.0035086. Epub 2012 Apr 9.

9.

Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Wang LC, Lynn RC, Cheng G, Alexander E, Kapoor V, Moon EK, Sun J, Fridlender ZG, Isaacs SN, Thorne SH, Albelda SM.

Mol Ther. 2012 Apr;20(4):736-48. doi: 10.1038/mt.2011.228. Epub 2011 Oct 18.

10.

The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Dehaven BC, Gupta K, Isaacs SN.

J Gen Virol. 2011 Sep;92(Pt 9):1971-80. doi: 10.1099/vir.0.030460-0. Epub 2011 Jun 29. Review.

11.

Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.

Cohen ME, Xiao Y, Eisenberg RJ, Cohen GH, Isaacs SN.

PLoS One. 2011;6(6):e20597. doi: 10.1371/journal.pone.0020597. Epub 2011 Jun 8.

12.
13.

The Vaccinia virus complement control protein modulates adaptive immune responses during infection.

Girgis NM, Dehaven BC, Xiao Y, Alexander E, Viner KM, Isaacs SN.

J Virol. 2011 Mar;85(6):2547-56. doi: 10.1128/JVI.01474-10. Epub 2010 Dec 29.

14.

A stimulating way to improve T cell responses to poxvirus-vectored vaccines.

Isaacs SN.

J Clin Invest. 2011 Jan;121(1):19-21. doi: 10.1172/JCI45726. Epub 2010 Dec 22.

15.

Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.

DeHaven BC, Girgis NM, Xiao Y, Hudson PN, Olson VA, Damon IK, Isaacs SN.

J Virol. 2010 Nov;84(21):11245-54. doi: 10.1128/JVI.00372-10. Epub 2010 Aug 18.

16.

A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.

Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN.

Vaccine. 2010 Sep 14;28(40):6627-36. doi: 10.1016/j.vaccine.2010.07.030. Epub 2010 Jul 24.

17.

Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.

Mustafa W, Maciag PC, Pan ZK, Weaver JR, Xiao Y, Isaacs SN, Paterson Y.

Viral Immunol. 2009 Jun;22(3):195-204. doi: 10.1089/vim.2008.0071.

18.

A role for the host coatomer and KDEL receptor in early vaccinia biogenesis.

Zhang L, Lee SY, Beznoussenko GV, Peters PJ, Yang JS, Gilbert HY, Brass AL, Elledge SJ, Isaacs SN, Moss B, Mironov A, Hsu VW.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):163-8. doi: 10.1073/pnas.0811631106. Epub 2008 Dec 24.

19.

Monkeypox virus and insights into its immunomodulatory proteins.

Weaver JR, Isaacs SN.

Immunol Rev. 2008 Oct;225:96-113. doi: 10.1111/j.1600-065X.2008.00691.x. Review.

20.

Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.

Girgis NM, Dehaven BC, Fan X, Viner KM, Shamim M, Isaacs SN.

J Virol. 2008 May;82(9):4205-14. doi: 10.1128/JVI.02426-07. Epub 2008 Feb 20.

21.

The identification and characterization of a monoclonal antibody to the vaccinia virus E3 protein.

Weaver JR, Shamim M, Alexander E, Davies DH, Felgner PL, Isaacs SN.

Virus Res. 2007 Dec;130(1-2):269-74. Epub 2007 Jun 20.

22.

Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6.

Aldaz-Carroll L, Xiao Y, Whitbeck JC, de Leon MP, Lou H, Kim M, Yu J, Reinherz EL, Isaacs SN, Eisenberg RJ, Cohen GH.

J Virol. 2007 Aug;81(15):8131-9. Epub 2007 May 23.

23.

Smallpox subunit vaccine produced in Planta confers protection in mice.

Golovkin M, Spitsin S, Andrianov V, Smirnov Y, Xiao Y, Pogrebnyak N, Markley K, Brodzik R, Gleba Y, Isaacs SN, Koprowski H.

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6864-9. Epub 2007 Apr 11.

24.

B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.

Viner KM, Girgis N, Kwak H, Isaacs SN.

Virology. 2007 May 10;361(2):356-63. Epub 2006 Dec 26.

25.

A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

Xiao Y, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, Davis HL, Braciale TJ, Eisenberg RJ, Cohen GH, Isaacs SN.

Vaccine. 2007 Jan 26;25(7):1214-24. Epub 2006 Oct 17.

26.

The envelope G3L protein is essential for entry of vaccinia virus into host cells.

Izmailyan RA, Huang CY, Mohammad S, Isaacs SN, Chang W.

J Virol. 2006 Sep;80(17):8402-10.

27.

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW.

Vaccine. 2006 Apr 24;24(17):3686-94.

PMID:
16430997
28.

Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.

Aldaz-Carroll L, Whitbeck JC, Ponce de Leon M, Lou H, Hirao L, Isaacs SN, Moss B, Eisenberg RJ, Cohen GH.

J Virol. 2005 May;79(10):6260-71.

29.

Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees.

Viner KM, Isaacs SN.

Microbes Infect. 2005 Apr;7(4):579-83. Epub 2005 Mar 22.

PMID:
15848274
30.

Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins.

Sfyroera G, Katragadda M, Morikis D, Isaacs SN, Lambris JD.

J Immunol. 2005 Feb 15;174(4):2143-51.

31.
32.
33.
34.
35.

Complement: structure, functions, evolution, and viral molecular mimicry.

Mastellos D, Morikis D, Isaacs SN, Holland MC, Strey CW, Lambris JD.

Immunol Res. 2003;27(2-3):367-86. Review.

PMID:
12857982
36.
37.

Critical evaluation of smallpox vaccination for laboratory workers.

Isaacs SN.

Occup Environ Med. 2002 Sep;59(9):573-4. No abstract available.

39.

Concordant utilization of macrophage entry coreceptors by related variants within an HIV type 1 primary isolate viral swarm.

Singh A, Yi Y, Isaacs SN, Kolson DL, Collman RG.

AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):957-63.

PMID:
11461681
41.

HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response.

Weissman D, Ni H, Scales D, Dude A, Capodici J, McGibney K, Abdool A, Isaacs SN, Cannon G, Karikó K.

J Immunol. 2000 Oct 15;165(8):4710-7.

42.
43.
44.
45.

Functional analysis of vaccinia virus B5R protein: role of the cytoplasmic tail.

Lorenzo MM, Herrera E, Blasco R, Isaacs SN.

Virology. 1998 Dec 20;252(2):450-7.

46.

Human 12(R)-lipoxygenase and the mouse ortholog. Molecular cloning, expression, and gene chromosomal assignment.

Sun D, McDonnell M, Chen XS, Lakkis MM, Li H, Isaacs SN, Elsea SH, Patel PI, Funk CD.

J Biol Chem. 1998 Dec 11;273(50):33540-7.

49.

Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25.

Quakyi IA, Miller LH, Good MF, Ahlers JD, Isaacs SN, Nunberg JH, Houghten RA, Keister DB, Coligan JE, Moss B, et al.

Pept Res. 1995 Nov-Dec;8(6):335-44.

PMID:
8838417
50.

Expression of hepatitis E virus putative structural proteins in recombinant vaccinia viruses.

Carl M, Isaacs SN, Kaur M, He J, Tam AW, Yarbough PO, Reyes GR.

Clin Diagn Lab Immunol. 1994 Mar;1(2):253-6.

Supplemental Content

Loading ...
Support Center